Clinical Trial: A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas(R), Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions

U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07091669) titled 'A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas(R), Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions' on July 22.

Brief Summary: The aim of this study is to evaluate the bioequivalence and safety of Tamsulosin hydrochloride 0.4 mg, prolonged-release tablets (Synthon Hispania SL, Spain), compared to Omnic Ocas(R), Tamsulosin hydrochloride 0,4 mg, prolonged-release film-coated tablets (Astellas Pharma Europe B.V., the Netherlands), after single dose administration in healthy adult male subjects under fed conditions.

Study Start Date...